Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Tim Leaver explains how his company has developed a proprietary technology for the rapid development of nanoparticles and seamless scale-up for clinical studies and commercial production, and how it is transforming the development and manufacturing of a range of nanoparticle formulations from a hit-and-miss affair to a standardized process, accelerating novel nanomedicines from the bench to the clinic.
SPECIAL FEATURE – Prefilled Syringes & Parenteral Manufacturing: A Rise in Biologics & Improved Technology Give Pharma Reasons to Consider Parenteral Delivery May 2, 2017
Contributor Cindy H. Dubin speaks with some of the leading companies in this market to find out about key trends, packaging advancements, safety improvements, and technology developments.
CONTROLLED RELEASE – Leveraging Precision Particle Fabrication® Technology to Create Patient-Friendly Dosage Forms May 2, 2017
Cory Berkland, PhD, and Nathan Dormer, PhD, review how controlled-release powders offer a flexible and efficient approach to addressing a multitude of patient populations, while also improving compliance.
SPECIAL FEATURE – Formulation Development & Manufacturing – CDMOs Offer Speed, Advanced Technologies, & the Ability to Handle More Potent APIs April 4, 2017
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs.
Aptose Prioritizes Development of First-in Class FLT3/BTK Inhibitor January 27, 2017Aptose Biosciences Inc. recently announced it will prioritize its resources toward the development of CG’806, an oral preclinical compound being...
FORMULATION DEVELOPMENT – Optimizing the Spray-Drying Parameters for a Formulation of Nanoparticles-In-Microparticles System of Acetazolamide January 16, 2017
Parijat Pandey, MPharm, and Harish Dureja, PhD, examine the consequence of spray-drying parameters that are inlet temperature and feed rpm on entrapment efficiency, loading capacity, percentage yield, and particle size.
ADVANCED DELIVERY DEVICES – Disruptive Delivery Technology Partnerships Are Key to Pharmaceutical Life Cycle Management January 16, 2017
Michael D. Hooven, MSME, believes in the challenge to deliver innovative therapies that address unmet patient needs while delivering profitable growth, and the industry is responding by embracing disruptive technology that can concurrently help on both fronts and also speed time to market for pharmaceutical products and services.
C3J Therapeutics Unveils Development of Two New Product Formulations December 20, 2016C3J Therapeutics, Inc. recently announced the development of two new formulations of its lead candidate, C16G2, a novel peptide-based drug...
Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.
Aptar Pharma Announces Development & License Agreement With BD September 2, 2016Aptar Pharma Announces Development & License Agreement With BD Aptar Pharma, a leading drug delivery solutions provider...
SOFTGEL FORMULATIONS – Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market August 30, 2016
Ronak Savla, PhD, PharmD, and Jeffrey E. Browne, PhD, indicate formulation screening, development, scale-up, and commercial manufacture of LBDDSs require considerable expertise, and choosing an outsourcing partner with experience and a proven track record is critical.
ORALLY DISINTEGRATING TABLETS – Designed With Patients in Mind: The Art of Patient-Centric Drug Formulation August 30, 2016
Anthony Recupero, PhD, believes by partnering with an expert in drug delivery technology, whose portfolio features a broad range of proprietary technologies, pharmaceutical companies have the potential to add further value to their products and extend market exclusivity.
DELIVERY PLATFORM – Encochleated Drug Formulations: Enhancing Efficacy, Minimizing Toxicity June 30, 2016
Roelof Rongen, MBA, MS, indicates drugs for serious fungal and microbial infections currently require IV administration at doses associated with significant toxicity. Orally administered, encochleated formulations of a broad-spectrum of fungicidal and anti-microbial medications may provide delivery of anti-infective drugs at therapeutic levels while minimizing drug-associated side effects.
GLOBAL FORMULATION REPORT – Notable Technologies, Approvals, Transactions, Pipelines & Inflection Points June 30, 2016
This Global Formulation Report is a joint initiative by Drug Development & Delivery and PharmaCircle LLC, covering several areas of significant interest in today’s ever-challenging pharmaceutical and biotechnology industries.
MICROBIAL PRODUCTION – Cutting-Edge inABLE® Technology: The Key to Cost-Effective Production of a Novel Antimicrobial Peptide With Potential for the Treatment of MRSA June 1, 2016
Ian Fotheringham, PhD, and Mathew Upton, PhD, report that Infections caused by antibiotic resistant bacteria are an ever-increasing threat to public health, creating an urgent, growing demand for the identification and development of new therapies.